Literature DB >> 4853607

Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia.

E E Ohnhaus, E Nüesch, J Meier, F Kalberer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4853607     DOI： 10.1007/bf00614386

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  7 in total

1.  The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis".

Authors:  N S BRICKER; P A MORRIN; S W KIME
Journal:  Am J Med       Date:  1960-01       Impact factor: 4.965

2.  [Pharmacokinetics of indomethacin in patients with kidney lesions].

Authors:  A Traeger; G Stein; M Kunze; J Zaumseil
Journal:  Int J Clin Pharmacol       Date:  1972-08

3.  Pharmacodynamics of propranolol in renal failure.

Authors:  F D Thompson; A M Joekes; D M Foulkes
Journal:  Br Med J       Date:  1972-05-20

4.  [Serum creatinine determination without protein precipitation].

Authors:  H Bartels; M Böhmer; C Heierli
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

5.  Multiple dose kinetics and drug dosage in patients with kidney disease.

Authors:  L Dettli; P Spring; S Ryter
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

6.  [Excretion of doxycycline and the effect of hemodialysis in anurid].

Authors:  M Mannhart; L Dettli; P Spring
Journal:  Schweiz Med Wochenschr       Date:  1971-01-30

7.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15
  7 in total
  19 in total

1.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 2.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.

Authors:  W H Frishman; E J Lazar; G Gorodokin
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

4.  Relationship between renal function and elimination kinetics of pindolol in man.

Authors:  S Oie; G Levy
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

5.  Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.

Authors:  J Meier; E Nüesch
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

6.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

7.  Pharmacokinetics of pindolol in Africans.

Authors:  L A Salako; A Ragon; R A Adio; A O Falase
Journal:  Experientia       Date:  1979-02-15

8.  Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Authors:  A Roux; P Aubert; J Guedon; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

9.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

10.  Metabolism of pindolol in patients with renal failure.

Authors:  E E Ohnhaus; H Heidemann; J Meier; G Maurer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.